Search

Your search keyword '"Soon, Jennifer A"' showing total 16 results
Start Over Author "Soon, Jennifer A"
16 results on '"Soon, Jennifer A"'

2. A tailored approach to horizon scanning for cancer medicines

Author

Soon, Jennifer A., To, Yat Hang, Alexander, Marliese, Trapani, Karen, Ascierto, Paolo A., Athan, Sophy, Brown, Michael P., Burge, Matthew, Haydon, Andrew, Hughes, Brett, Itchins, Malinda, John, Thomas, Kao, Steven, Koopman, Miriam, Li, Bob T., Long, Georgina V., Loree, Jonathan M., Markman, Ben, Meniawy, Tarek M., Menzies, Alexander M., Nott, Louise, Pavlakis, Nick, Petrella, Teresa M., Popat, Sanjay, Tie, Jeanne, Xu, Wen, Yip, Desmond, Zalcberg, John, Solomon, Benjamin J., Gibbs, Peter, McArthur, Grant A., Franchini, Fanny, and IJzerman, Maarten

Published
2023
Full Text
View/download PDF

3. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study

Author

Müller-Jensen, Leonie, Zierold, Sarah, Versluis, Judith M., Boehmerle, Wolfgang, Huehnchen, Petra, Endres, Matthias, Mohr, Raphael, Compter, Annette, Blank, Christian U., Hagenacker, Tim, Meier, Friedegund, Reinhardt, Lydia, Gesierich, Anja, Salzmann, Martin, Hassel, Jessica C., Ugurel, Selma, Zimmer, Lisa, Banks, Patricia, Spain, Lavinia, Soon, Jennifer A., Enokida, Tomohiro, Tahara, Makoto, Kähler, Katharina C., Seggewiss-Bernhardt, Ruth, Harvey, Catriona, Long, Georgina V., Schöberl, Florian, von Baumgarten, Louisa, Hundsberger, Thomas, Schlaak, Max, French, Lars E., Knauss, Samuel, and Heinzerling, Lucie M.

Published
2022
Full Text
View/download PDF

6. A tailored approach to horizon scanning for cancer medicines

Author

Soon, Jennifer A, To, Yat Hang, Alexander, Marliese, Trapani, Karen, Ascierto, Paolo A, Athan, Sophy, Burge, Matthew, Haydon, Andrew, Hughes, Brett, Itchins, Malinda, John, Thomas, Kao, Steven, Koopman, Miriam, Li, Bob T, Long, Georgina V, Loree, Jonathan M, Markman, Ben, Meniawy, Tarek M, Menzies, Alexander M, Nott, Louise, Pavlakis, Nick, Petrella, Teresa M, Popat, Sanjay, Tie, Jeanne, Xu, Wen, Yip, Desmond, Zalcberg, John, Solomon, Benjamin J, Gibbs, Peter, McArthur, Grant A, Franchini, Fanny, IJzerman, Maarten, Soon, Jennifer A, To, Yat Hang, Alexander, Marliese, Trapani, Karen, Ascierto, Paolo A, Athan, Sophy, Burge, Matthew, Haydon, Andrew, Hughes, Brett, Itchins, Malinda, John, Thomas, Kao, Steven, Koopman, Miriam, Li, Bob T, Long, Georgina V, Loree, Jonathan M, Markman, Ben, Meniawy, Tarek M, Menzies, Alexander M, Nott, Louise, Pavlakis, Nick, Petrella, Teresa M, Popat, Sanjay, Tie, Jeanne, Xu, Wen, Yip, Desmond, Zalcberg, John, Solomon, Benjamin J, Gibbs, Peter, McArthur, Grant A, Franchini, Fanny, and IJzerman, Maarten

Abstract

BACKGROUND: Horizon scanning (HS) is the systematic identification of emerging therapies to inform policy and decision-makers. We developed an agile and tailored HS methodology that combined multi-criteria decision analysis weighting and Delphi rounds. As secondary objectives, we aimed to identify new medicines in melanoma, non-small cell lung cancer and colorectal cancer most likely to impact the Australian government's pharmaceutical budget by 2025 and to compare clinician and consumer priorities in cancer medicine reimbursement.METHOD: Three cancer-specific clinician panels (total n = 27) and a consumer panel (n = 7) were formed. Six prioritisation criteria were developed with consumer input. Criteria weightings were elicited using the Analytic Hierarchy Process (AHP). Candidate medicines were identified and filtered from a primary database and validated against secondary and tertiary sources. Clinician panels participated in a three-round Delphi survey to identify and score the top five medicines in each cancer type.RESULTS: The AHP and Delphi process was completed in eight weeks. Prioritisation criteria focused on toxicity, quality of life (QoL), cost savings, strength of evidence, survival, and unmet need. In both curative and non-curative settings, consumers prioritised toxicity and QoL over survival gains, whereas clinicians prioritised survival. HS results project the ongoing prevalence of high-cost medicines. Since completion in October 2021, the HS has identified 70 % of relevant medicines submitted for Pharmaceutical Benefit Advisory Committee assessment and 60% of the medicines that received a positive recommendation.CONCLUSION: Tested in the Australian context, our method appears to be an efficient and flexible approach to HS that can be tailored to address specific disease types by using elicited weights to prioritise according to incremental value from both a consumer and clinical perspective.POLICY SUMMARY: Since HS is

Published
2023

7. A tailored approach to horizon scanning for cancer medicines

Author

MS Medische Oncologie, Cancer, Soon, Jennifer A, To, Yat Hang, Alexander, Marliese, Trapani, Karen, Ascierto, Paolo A, Athan, Sophy, Brown, Michael P, Burge, Matthew, Haydon, Andrew, Hughes, Brett, Itchins, Malinda, John, Thomas, Kao, Steven, Koopman, Miriam, Li, Bob T, Long, Georgina V, Loree, Jonathan M, Markman, Ben, Meniawy, Tarek M, Menzies, Alexander M, Nott, Louise, Pavlakis, Nick, Petrella, Teresa M, Popat, Sanjay, Tie, Jeanne, Xu, Wen, Yip, Desmond, Zalcberg, John, Solomon, Benjamin J, Gibbs, Peter, McArthur, Grant A, Franchini, Fanny, IJzerman, Maarten, MS Medische Oncologie, Cancer, Soon, Jennifer A, To, Yat Hang, Alexander, Marliese, Trapani, Karen, Ascierto, Paolo A, Athan, Sophy, Brown, Michael P, Burge, Matthew, Haydon, Andrew, Hughes, Brett, Itchins, Malinda, John, Thomas, Kao, Steven, Koopman, Miriam, Li, Bob T, Long, Georgina V, Loree, Jonathan M, Markman, Ben, Meniawy, Tarek M, Menzies, Alexander M, Nott, Louise, Pavlakis, Nick, Petrella, Teresa M, Popat, Sanjay, Tie, Jeanne, Xu, Wen, Yip, Desmond, Zalcberg, John, Solomon, Benjamin J, Gibbs, Peter, McArthur, Grant A, Franchini, Fanny, and IJzerman, Maarten

Published
2023

8. Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis

Author

Müller-Jensen, Leonie, primary, Zierold, Sarah, additional, Versluis, Judith M, additional, Boehmerle, Wolfgang, additional, Huehnchen, Petra, additional, Endres, Matthias, additional, Mohr, Raphael, additional, Compter, Annette, additional, Blank, Christian U, additional, Hagenacker, Tim, additional, Meier, Friedegund, additional, Reinhardt, Lydia, additional, Gesierich, Anja, additional, Salzmann, Martin, additional, Hassel, Jessica C, additional, Ugurel, Selma, additional, Zimmer, Lisa, additional, Banks, Patricia, additional, Spain, Lavinia, additional, Soon, Jennifer A, additional, Enokida, Tomohiro, additional, Tahara, Makoto, additional, Kähler, Katharina C, additional, Seggewiss-Bernhardt, Ruth, additional, Harvey, Catriona, additional, Long, Georgina V, additional, Schöberl, Florian, additional, von Baumgarten, Louisa, additional, Hundsberger, Thomas, additional, Schlaak, Max, additional, French, Lars E, additional, Knauss, Samuel, additional, and Heinzerling, Lucie M, additional

Published
2022
Full Text
View/download PDF

9. Patterns and management of progression on first-line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients.

Author

Pires Da Silva, Ines, primary, Versluis, Judith M., additional, Ahmed, Tasnia, additional, Johnson, Douglas Buckner, additional, Soon, Jennifer, additional, Allayous, Clara, additional, Gerard, Camille Lea, additional, Mangana, Joanna, additional, Klein, Oliver, additional, Zimmer, Lisa, additional, Robert, Caroline, additional, Vitale, Maria Grazia, additional, Yeoh, Hui-Ling, additional, Michielin, Olivier, additional, Lebbe, Celeste, additional, Sandhu, Shahneen Kaur, additional, Blank, Christian U., additional, Carlino, Matteo S., additional, Menzies, Alexander M., additional, and Long, Georgina V., additional

Published
2021
Full Text
View/download PDF

10. Combined ipilimumab and nivolumab first‐line and after BRAF‐targeted therapy in advanced melanoma

Author

Mason, Robert, primary, Dearden, Helen C., additional, Nguyen, Bella, additional, Soon, Jennifer A., additional, Smith, Jessica Louise, additional, Randhawa, Manreet, additional, Mant, Andrew, additional, Warburton, Lydai, additional, Lo, Serigne, additional, Meniawy, Tarek, additional, Guminski, Alexander, additional, Parente, Phillip, additional, Ali, Sayed, additional, Haydon, Andrew, additional, Long, Georgina V., additional, Carlino, Matteo S., additional, Millward, Michael, additional, Atkinson, Victoria G., additional, and Menzies, Alexander M., additional

Published
2019
Full Text
View/download PDF

13. Combined ipilimumab and nivolumab first‐line and after BRAF‐targeted therapy in advanced melanoma.

Author

Mason, Robert, Dearden, Helen C., Nguyen, Bella, Soon, Jennifer A., Smith, Jessica Louise, Randhawa, Manreet, Mant, Andrew, Warburton, Lydai, Lo, Serigne, Meniawy, Tarek, Guminski, Alexander, Parente, Phillip, Ali, Sayed, Haydon, Andrew, Long, Georgina V., Carlino, Matteo S., Millward, Michael, Atkinson, Victoria G., and Menzies, Alexander M.

Subjects
BRAF genes, MELANOMA, SERINE/THREONINE kinases, PROGRESSION-free survival
Abstract

The combination of ipilimumab and nivolumab is a highly active systemic therapy for metastatic melanoma but can cause significant toxicity. We explore the safety and efficacy of this treatment in routine clinical practice, particularly in the setting of serine/threonine‐protein kinase B‐Raf (BRAF)‐targeted therapy. Consecutive patients with unresectable stage IIIC/IV melanoma commenced on ipilimumab and nivolumab across 10 tertiary melanoma institutions in Australia were identified retrospectively. Data collected included demographics, response and survival outcomes. A total of 152 patients were included for analysis, 39% were treatment‐naïve and 22% failed first‐line BRAF/MEK inhibitors. Treatment‐related adverse events occurred in 67% of patients, grade 3–5 in 38%. The overall objective response rate was 41%, 57% in treatment‐naïve and 21% in BRAF/MEK failure patients. Median progression‐free survival was 4.0 months (95% CI, 3.0–6.0) in the whole cohort, 11.0 months (95% CI, 6.0‐NR) in treatment‐naïve and 2.0 months (95% CI, 1.4–4.6) in BRAF/MEK failure patients. The combination of ipilimumab and nivolumab can be used safely and effectively in a real‐world population. While first‐line efficacy appears comparable to trial populations, BRAF‐mutant patients failing prior BRAF/MEK inhibitors show less response. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results